Research graph
References from Bispecific antibody-drug conjugates in cancer: therapeutic-window determinants, tumour-immune interactions, and clinical translation. Local targets link to admitted publications; unresolved targets remain external evidence.
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
10.3322/caac.21834 · 2024 · External reference
Antibody drug conjugate: The "biological missile" for targeted cancer therapy
10.1038/s41392-022-00947-7 · 2022 · External reference
Unlocking the potential of antibody-drug conjugates for cancer therapy
10.1038/s41571-021-00470-8 · 2021 · External reference
The therapeutic window of antibody drug conjugates: A dogma in need of revision
10.1016/j.ccell.2022.09.016 · 2022 · External reference
Unlocking the potential of bispecific ADCs for targeted cancer therapy
10.1007/s11684-024-1072-8 · 2024 · External reference
Bispecific antibody drug conjugates: Making 1+1>2
10.1016/j.apsb.2024.01.009 · 2024 · External reference
Exploring the next generation of antibody-drug conjugates
10.1038/s41571-023-00850-2 · 2024 · External reference
SystImmune announces first approval of iza-bren for the treatment of recurrent or metastatic nasopharyngeal carcinoma in China
2026 · External reference
SystImmune announces second approval of iza-bren in China for the treatment of recurrent or metastatic esophageal squamous cell carcinoma
2026 · External reference
Bispecific antibody-drug conjugates: A modular blueprint for next-generation cancer therapeutics
10.1007/s12272-026-01595-z · 2026 · External reference
Antibody-drug conjugates (ADCs): Current and future biopharmaceuticals
10.1186/s13045-025-01704-3 · 2025 · External reference
Mechanisms of ADC toxicity and strategies to increase ADC tolerability
10.3390/cancers15030713 · 2023 · External reference
Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates
10.1080/19420862.2016.1156829 · 2016 · External reference
Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index
10.1038/nbt.3212 · 2015 · External reference
Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity
10.1111/cas.12966 · 2016 · External reference
Antibody-drug conjugate sacituzumab govitecan drives efficient tissue penetration and rapid intracellular drug release
10.1158/1535-7163.mct-22-0375 · 2023 · External reference
Mechanisms of resistance to antibody-drug conjugates
10.3390/ijms24119674 · 2023 · External reference
A bispecific antibody-drug conjugate targeting EGFR and HER3 in metastatic esophageal squamous cell carcinoma: A phase 1b trial
10.1038/s41591-025-03792-7 · 2025 · External reference
Patterns of EGFR and HER3 co-expression in solid tumors
10.1158/1538-7445.am2024-6190 · 2024 · External reference
A biparatopic HER2-targeting antibody-drug conjugate induces tumor regression in primary models refractory to or ineligible for HER2-targeted therapy
10.1016/j.ccell.2015.12.008 · 2016 · External reference
A biparatopic antibody-drug conjugate to treat MET-expressing cancers, including those that are unresponsive to MET pathway blockade
10.1158/1535-7163.mct-21-0009 · 2021 · External reference
First-in-human, phase 1 dose-escalation study of biparatopic anti-HER2 antibody-drug conjugate MEDI4276 in patients with HER2-positive advanced breast or gastric cancer
10.1158/1535-7163.mct-20-0014 · 2021 · External reference
A biparatopic HER2-targeting ADC constructed via site-specific glycan conjugation exhibits superior stability, safety, and efficacy
10.1039/d5cb00096c · 2025 · External reference
A review of conjugation technologies for antibody drug conjugates
10.1093/abt/tbaf010 · 2025 · External reference
Preclinical study of a biparatopic METxMET antibody-drug conjugate, REGN5093-M114, overcomes MET-driven acquired resistance to EGFR TKIs in EGFR-mutant NSCLC
10.1158/1078-0432.ccr-22-2180 · 2023 · External reference
BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: A first-in-human, open-label, multicentre, phase 1 study
10.1016/s1470-2045(24)00159-1 · 2024 · External reference
Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologies
10.3322/caac.21705 · 2022 · External reference
Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer
10.1056/nejmoa2203690 · 2022 · External reference
Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated non-small cell lung cancer
10.1158/2159-8290.cd-21-0715 · 2022 · External reference
Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer
10.1056/nejmoa2115022 · 2022 · External reference
Enfortumab vedotin in previously treated advanced urothelial carcinoma
10.1056/nejmoa2035807 · 2021 · External reference
Sacituzumab govitecan in metastatic triple-negative breast cancer
10.1056/nejmoa2028485 · 2021 · External reference
A HER2-targeting antibody-drug conjugate, trastuzumab deruxtecan (DS-8201a), enhances antitumor immunity in a mouse model
10.1158/1535-7163.mct-17-0749 · 2018 · External reference
Antibody-drug conjugates bearing pyrrolobenzodiazepine or tubulysin payloads are immunomodulatory and synergize with multiple immunotherapies
10.1158/0008-5472.can-16-2854 · 2017 · External reference
Patritumab deruxtecan induces immunogenic cell death
10.1080/2162402x.2025.2514050 · 2025 · External reference
Fcγ receptor-dependent internalization and off-target cytotoxicity of antibody-drug conjugate aggregates
10.1007/s11095-021-03158-x · 2022 · External reference
Izalontamab brengitecan, an EGFR and HER3 bispecific antibody-drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: A multicentre, randomised, open-label, phase 3 study in China
10.1016/s0140-6736(25)01954-3 · 2025 · External reference
Izalontamab brengitecan (iza-bren) versus chemotherapy in patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC): A multicenter, randomized, open-label, phase III study
10.1200/jco.2026.44.16_suppl.4008 · 2026 · External reference
Izalontamab brengitecan (iza-bren) versus physician’s choice of chemotherapy in patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC): A randomized phase III study
10.1200/jco.2026.44.17_suppl.lba1003 · 2026 · External reference
Izalontamab brengitecan (EGFRxHER3 ADC) granted Breakthrough Therapy Designation by U.S. FDA for patients with previously treated advanced EGFR-mutated non-small cell lung cancer
2025 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Izalontamab brengitecan in locally advanced or metastatic non-small cell lung cancer with actionable genomic alterations outside of classical EGFR mutations: A Phase Ib study
10.1200/jco-25-01929 · 2026 · External reference
Izalontamab brengitecan (iza-bren), a first-in-class EGFR-HER3 bispecific antibody-drug conjugate in extensive-stage small cell lung cancer: Results from a Phase Ib study
10.1200/jco-26-00243 · 2026 · External reference
Efficacy and safety of BL-B01D1 in patients with locally advanced or metastatic urothelial carcinoma: A Phase II clinical trial
10.1200/jco-25-00109 · 2025 · External reference
JSKN016, a first-in-class anti-TROP2/HER3 bispecific antibody-drug conjugate (ADC), in patients with HER2-negative locally advanced or metastatic breast cancer: Results from a phase I study
10.1200/jco.2026.44.16_suppl.1123 · 2026 · External reference
JSKN003 pipeline and registrational development update
2026 · External reference
A study to assess change in disease activity and adverse events in adult participants with gynecologic cancers receiving IMGN151 (NCT07024784)
2026 · External reference
First-in-human study of DM005, an anti-EGFR/c-MET bispecific antibody-drug conjugate, in patients with advanced solid tumors
10.1200/jco.2026.44.16_suppl.8530 · 2026 · External reference
First in human study of AZD9592 in solid tumors - EGRET (NCT05647122)
2026 · External reference
Henlius doses first patient with c-MET x EGFR bispecific ADC HLX48
2026 · External reference
Zymeworks provides corporate update and reports second quarter 2024 financial results
2024 · External reference
Study of REGN5093-M114 (METxMET antibody-drug conjugate) in adult patients with MET-overexpressing advanced cancer (NCT04982224)
2025 · External reference
Alphamab Oncology announces the first patient dosed in a Phase I clinical study of EGFR/HER3 dual payload bispecific ADC JSKN021
2026 · External reference
Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer
10.1056/nejmoa2312117 · 2024 · External reference
Disitamab vedotin (RC48) plus toripalimab for HER2-expressing advanced gastric or gastroesophageal junction and other solid tumours: A multicentre, open label, dose escalation and expansion phase 1 trial
10.1016/j.eclinm.2023.102415 · 2024 · External reference
Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity
10.1038/s43018-020-00136-x · 2021 · External reference
When will the immune-stimulating antibody conjugates (ISACs) be transferred from bench to bedside
10.1016/j.phrs.2024.107160 · 2024 · External reference
Targeted delivery of a potent STING agonist payload via an antibody-drug conjugate drives robust antitumor activity in preclinical models
10.1158/1535-7163.mct-25-0108 · 2026 · External reference
DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1
10.1158/1078-0432.ccr-15-2822 · 2016 · External reference
Fcγ receptor-dependent internalization and off-target cytotoxicity of antibody-drug conjugate aggregates
10.1007/s11095-021-03158-x · ExternalCitation · doi-reference
Unlocking the potential of bispecific ADCs for targeted cancer therapy
10.1007/s11684-024-1072-8 · ExternalCitation · doi-reference
Bispecific antibody-drug conjugates: A modular blueprint for next-generation cancer therapeutics
10.1007/s12272-026-01595-z · ExternalCitation · doi-reference
Bispecific antibody drug conjugates: Making 1+1>2
10.1016/j.apsb.2024.01.009 · ExternalCitation · doi-reference
A biparatopic HER2-targeting antibody-drug conjugate induces tumor regression in primary models refractory to or ineligible for HER2-targeted therapy
10.1016/j.ccell.2015.12.008 · ExternalCitation · doi-reference
The therapeutic window of antibody drug conjugates: A dogma in need of revision
10.1016/j.ccell.2022.09.016 · ExternalCitation · doi-reference
Disitamab vedotin (RC48) plus toripalimab for HER2-expressing advanced gastric or gastroesophageal junction and other solid tumours: A multicentre, open label, dose escalation and expansion phase 1 trial
10.1016/j.eclinm.2023.102415 · ExternalCitation · doi-reference
When will the immune-stimulating antibody conjugates (ISACs) be transferred from bench to bedside
10.1016/j.phrs.2024.107160 · ExternalCitation · doi-reference
Izalontamab brengitecan, an EGFR and HER3 bispecific antibody-drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: A multicentre, randomised, open-label, phase 3 study in China
10.1016/s0140-6736(25)01954-3 · ExternalCitation · doi-reference
BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: A first-in-human, open-label, multicentre, phase 1 study
10.1016/s1470-2045(24)00159-1 · ExternalCitation · doi-reference
Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index
10.1038/nbt.3212 · ExternalCitation · doi-reference
Antibody drug conjugate: The "biological missile" for targeted cancer therapy
10.1038/s41392-022-00947-7 · ExternalCitation · doi-reference
Unlocking the potential of antibody-drug conjugates for cancer therapy
10.1038/s41571-021-00470-8 · ExternalCitation · doi-reference
Exploring the next generation of antibody-drug conjugates
10.1038/s41571-023-00850-2 · ExternalCitation · doi-reference
A bispecific antibody-drug conjugate targeting EGFR and HER3 in metastatic esophageal squamous cell carcinoma: A phase 1b trial
10.1038/s41591-025-03792-7 · ExternalCitation · doi-reference
Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity
10.1038/s43018-020-00136-x · ExternalCitation · doi-reference
A biparatopic HER2-targeting ADC constructed via site-specific glycan conjugation exhibits superior stability, safety, and efficacy
10.1039/d5cb00096c · ExternalCitation · doi-reference
Sacituzumab govitecan in metastatic triple-negative breast cancer
10.1056/nejmoa2028485 · ExternalCitation · doi-reference
Enfortumab vedotin in previously treated advanced urothelial carcinoma
10.1056/nejmoa2035807 · ExternalCitation · doi-reference
Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer
10.1056/nejmoa2115022 · ExternalCitation · doi-reference
Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer
10.1056/nejmoa2203690 · ExternalCitation · doi-reference
Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer
10.1056/nejmoa2312117 · ExternalCitation · doi-reference
Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates
10.1080/19420862.2016.1156829 · ExternalCitation · doi-reference
Patritumab deruxtecan induces immunogenic cell death
10.1080/2162402x.2025.2514050 · ExternalCitation · doi-reference
A review of conjugation technologies for antibody drug conjugates
10.1093/abt/tbaf010 · ExternalCitation · doi-reference
Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity
10.1111/cas.12966 · ExternalCitation · doi-reference
Antibody-drug conjugates bearing pyrrolobenzodiazepine or tubulysin payloads are immunomodulatory and synergize with multiple immunotherapies
10.1158/0008-5472.can-16-2854 · ExternalCitation · doi-reference
DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1
10.1158/1078-0432.ccr-15-2822 · ExternalCitation · doi-reference
Preclinical study of a biparatopic METxMET antibody-drug conjugate, REGN5093-M114, overcomes MET-driven acquired resistance to EGFR TKIs in EGFR-mutant NSCLC
10.1158/1078-0432.ccr-22-2180 · ExternalCitation · doi-reference
A HER2-targeting antibody-drug conjugate, trastuzumab deruxtecan (DS-8201a), enhances antitumor immunity in a mouse model
10.1158/1535-7163.mct-17-0749 · ExternalCitation · doi-reference
First-in-human, phase 1 dose-escalation study of biparatopic anti-HER2 antibody-drug conjugate MEDI4276 in patients with HER2-positive advanced breast or gastric cancer
10.1158/1535-7163.mct-20-0014 · ExternalCitation · doi-reference
A biparatopic antibody-drug conjugate to treat MET-expressing cancers, including those that are unresponsive to MET pathway blockade
10.1158/1535-7163.mct-21-0009 · ExternalCitation · doi-reference
Antibody-drug conjugate sacituzumab govitecan drives efficient tissue penetration and rapid intracellular drug release
10.1158/1535-7163.mct-22-0375 · ExternalCitation · doi-reference
Targeted delivery of a potent STING agonist payload via an antibody-drug conjugate drives robust antitumor activity in preclinical models
10.1158/1535-7163.mct-25-0108 · ExternalCitation · doi-reference
Patterns of EGFR and HER3 co-expression in solid tumors
10.1158/1538-7445.am2024-6190 · ExternalCitation · doi-reference
Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated non-small cell lung cancer
10.1158/2159-8290.cd-21-0715 · ExternalCitation · doi-reference
Antibody-drug conjugates (ADCs): Current and future biopharmaceuticals
10.1186/s13045-025-01704-3 · ExternalCitation · doi-reference
Efficacy and safety of BL-B01D1 in patients with locally advanced or metastatic urothelial carcinoma: A Phase II clinical trial
10.1200/jco-25-00109 · ExternalCitation · doi-reference
Izalontamab brengitecan in locally advanced or metastatic non-small cell lung cancer with actionable genomic alterations outside of classical EGFR mutations: A Phase Ib study
10.1200/jco-25-01929 · ExternalCitation · doi-reference
Izalontamab brengitecan (iza-bren), a first-in-class EGFR-HER3 bispecific antibody-drug conjugate in extensive-stage small cell lung cancer: Results from a Phase Ib study
10.1200/jco-26-00243 · ExternalCitation · doi-reference
JSKN016, a first-in-class anti-TROP2/HER3 bispecific antibody-drug conjugate (ADC), in patients with HER2-negative locally advanced or metastatic breast cancer: Results from a phase I study
10.1200/jco.2026.44.16_suppl.1123 · ExternalCitation · doi-reference
Izalontamab brengitecan (iza-bren) versus chemotherapy in patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC): A multicenter, randomized, open-label, phase III study
10.1200/jco.2026.44.16_suppl.4008 · ExternalCitation · doi-reference
First-in-human study of DM005, an anti-EGFR/c-MET bispecific antibody-drug conjugate, in patients with advanced solid tumors
10.1200/jco.2026.44.16_suppl.8530 · ExternalCitation · doi-reference
Izalontamab brengitecan (iza-bren) versus physician’s choice of chemotherapy in patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC): A randomized phase III study
10.1200/jco.2026.44.17_suppl.lba1003 · ExternalCitation · doi-reference
Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologies
10.3322/caac.21705 · ExternalCitation · doi-reference
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
10.3322/caac.21834 · ExternalCitation · doi-reference
Mechanisms of ADC toxicity and strategies to increase ADC tolerability
10.3390/cancers15030713 · ExternalCitation · doi-reference
Mechanisms of resistance to antibody-drug conjugates
10.3390/ijms24119674 · ExternalCitation · doi-reference
